StockNews.AISignal intelligence

Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

Browse signals
AMGNBullishEarningsnews
High materiality9/10

Amgen delivers solid Q3 growth; Repatha and MariTide progress bolster pipeline

Nov 3, 2026, 4:22 PM EST1 sourcesAI-analyzed
Why it may matterVerify against the original reporting

Strong Q3 results, meaningful EPS uplift, and intact 2026 guidance typically drive modest near-term upside; dividend increase signals capital returns. Biosimilar pressure on Prolia is a risk, but pipeline momentum (MariTide, Repatha) provides offsetting catalysts.

AI summary

What happened, with direct paths to the underlying reporting

Amgen reported Q3 2026 results with revenue of $10.4B, an 8% YoY rise, and GAAP EPS of $7.08. Growth was led by Repatha and Evenity, while Prolia faced biosimilar pressure. Pipeline updates on MariTide and strong Repatha CV signals offer near-term catalysts, and the 2026 guidance remains intact, signaling durable cash flow and long-term value creation.

  • Amgen Q3'26 revenue $10.4B, up 8% YoY; GAAP EPS $7.08, non-GAAP $6.45.
  • Repatha and Evenity drive growth; Prolia biosimilars weigh on sales.
  • Free cash flow $3.7B; dividend up 6%; no share repurchases in Q3.
  • 2026 guidance: revenue $38.9–$39.7B; non-GAAP EPS $22.90–$23.70; capex ~$2.6B; buybacks up to $3B.
  • MariTide Phase 3 progress; Repatha CV mortality signals; OCEAN(a) trials ongoing.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Related signals

More source-backed signals connected by company or event